Faslg Fas Ligand is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Overview |
|---|
| Gene Symbol | FASLG |
| Full Name | Fas Ligand (TNF Superfamily Member 6) |
| Chromosomal Location | 1q23 |
| Protein Product | Fas Ligand (FasL/CD95L) |
| Molecular Weight | ~40 kDa (membrane), ~26 kDa (soluble) |
| Gene Family | TNF superfamily |
The FASLG gene encodes Fas ligand (FasL/CD95L), a member of the tumor necrosis factor (TNF) superfamily. FasL is a type II transmembrane protein that binds to its receptor Fas (CD95), triggering apoptosis in cells expressing Fas. This death receptor pathway is essential for immune homeostasis, cytotoxic T cell function, and the regulation of autoreactive cells. Dysregulation of the Fas-FasL system contributes to various diseases, including autoimmune conditions and neurodegenerative disorders.
The FASLG gene is located on chromosome 1q23 and consists of 4 exons encoding a 281-amino acid type II membrane protein. The promoter region contains regulatory elements responsive to transcription factors including NF-κB, AP-1, and p53, allowing complex regulation of expression.
FasL is a type II transmembrane protein:
- N-terminal cytoplasmic tail: Short, ~20 amino acids
- Transmembrane domain: Single pass
- C-terminal extracellular domain: Contains TNF homology domain
- Trimer formation: Functional FasL forms trimers
- Proteolytic cleavage: Generates soluble FasL (less active)
Soluble FasL can be generated by metalloproteinase cleavage (MMP-7, MMP-9).
The Fas-FasL system mediates critical functions:
- Apoptosis induction: Triggers caspase cascade via Fas-associated death domain (FADD)
- Immune privilege: Protects certain tissues from immune attack
- Cytotoxic T cell function: Essential for target cell killing
- Negative selection: Removes autoreactive thymocytes
- Peripheral tolerance: Eliminates activated T cells
- Immune homeostasis: Maintains lymphocyte numbers
- Cancer immune surveillance: Eliminates transformed cells
FasL is expressed in:
- Cytotoxic T lymphocytes: Activated CD8+ T cells
- Natural killer cells: NK cell-mediated cytotoxicity
- Neutrophils: At sites of inflammation
- Certain neurons: In brain development
- Immune privilege sites: Eyes, testes, placenta
- Endothelial cells: Inflammatory conditions
Fas is widely expressed on most nucleated cells.
- FasL elevated in AD brain
- Contributes to neuronal apoptosis through:
- Caspase-8 activation
- Mitochondrial pathway engagement
- Dendritic spine loss
- Expressed by microglia and astrocytes
- Fas-FasL in synaptic dysfunction
- Potential therapeutic target
- FasL upregulated in substantia nigra of PD patients
- Contributes to dopaminergic neuron death
- Activated microglia express FasL
- Excitotoxicity enhances Fas-FasL signaling
- Therapeutic modulation under investigation
- Fas-FasL pathway activated in ALS
- Contributes to motor neuron apoptosis
- Expressed by reactive astrocytes
- Correlates with disease progression
- FasL blocking strategies protective in models
- FasL involved in demyelination
- Oligodendrocyte death via Fas-FasL
- Autoimmune attack on myelin
- Therapeutic potential of modulation
- Systemic lupus erythematosus: Defective FasL expression
- Autoimmune lymphoproliferative syndrome: FAS/FASLG mutations
- Type 1 diabetes: Fas-mediated β-cell death
- Rheumatoid arthritis: Synovial FasL expression
- Tumor cells often express FasL to kill infiltrating T cells
- "Immune evasion" mechanism
- Soluble FasL has opposing effects
| Approach |
Status |
Notes |
| Fas/FasL antagonists |
Preclinical |
Blocking antibodies |
| Caspase inhibitors |
Clinical |
Broader anti-apoptotic |
| Gene therapy |
Research |
Targeted delivery |
| Neuroprotective agents |
Research |
Downstream targets |
- Cell-type specific effects: Neuronal vs immune Fas signaling
- Therapeutic windows: Timing of intervention
- Biomarkers: Soluble FasL as marker
- Combination therapy: With other neuroprotective agents
- Delivery methods: CNS-targeted approaches
The study of Faslg Fas Ligand has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Krammer PH, et al. The CD95(APO-1/Fas)-CD95L system. Adv Exp Med Biol. 2000;477:293-302. PMID:10850064
- Wajant H. The Fas signaling pathway. J Cell Sci. 2002;115(Pt 4):703-704. PMID:11865022
- Beier CP, et al. FasL in neurodegeneration. Cell Tissue Res. 2003;314(1):85-96. PMID:14578993
- Vila M, et al. Fas in Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98(5):2837-2842. PMID:11226327
- Raoul C, et al. Fas and ALS. Nat Rev Neurosci. 2002;3(10):799-809. PMID:12360352
- Desbarats J, et al. FasL in autoimmune disease. Nat Med. 2003;9(1):29-30. PMID:12514716
- Letellier E, et al. CD95L in cancer immune evasion. Nat Rev Cancer. 2022;22(2):101-113. PMID:34759382
- Park C, et al. Targeting Fas/FasL in neurodegeneration. Neurobiol Dis. 2020;141:104958. PMID:32502689